Morning for Irofulven, What Could be fiNER? Available to Purchase

Cancers with DNA repair dysfunction are vulnerable to DNA-damaging agents that invoke a requirement for the disabled repair mechanism. Genome sequencing, coupled with a detailed understanding of mechanisms of DNA repair, has accelerated the discovery of pathway-selective agents that target DNA repair deficiencies in a tumor tissue agnostic manner.

See related articles by Topka et al., p. 1997 and Börcsök et al., p. 2011